Biomarkers in women's cancers, gynecology, and obstetrics.

Permalink
https://escholarship.org/uc/item/2xm724x7

Journal
BioMed research international, 2014

ISSN
2314-6133

Authors
Fasching, Peter A
Konecny, Gottfried E
Spurdle, Amanda B

Publication Date
2014

DOI
10.1155/2014/602340

Peer reviewed
More than 10 years after the publication of the reference sequence of the human genome several advances in biomarker discovery in obstetrics and gynecology and women’s cancer research have been made. Genome-wide studies aiming at the identification of pathophysiologically relevant novel genes and pathways have discovered multiple previously unknown molecular mechanisms, and this has fostered a new phase of candidate gene and pathway research that is informed by complex genetic, biological, and bioinformatic data. Technological advances have permitted biomarker research on all levels of systems biology (Table 1). In breast and ovarian cancer large consortia have genotyped germline DNA of more than 60,000 cancer patients and more than 60,000 controls for more than 200,000 single nucleotide polymorphisms [1, 2]. Moreover, several comprehensive reports have been published that decipher breast, ovarian, and endometrial cancer at all levels of gene regulation [3–5]. The ability to study circulating DNA through noninvasive sampling of blood is one of the most exciting and rapidly advancing fields in obstetrics and gynecology and cancer diagnostics. These advances now also enable the analysis of fetal DNA, which is circulating in the blood stream of the mother [6]. These developments have been driven not only by major technological advances, including the isolation of intact cancer cells and the analysis of cancer cell-derived DNA from blood samples, but also by the improvement of the sensitivity of analytic methods. Analysis of free circulating fetal DNA will change the diagnostic approach in prenatal medicine drastically. Moreover, in cancer research a “liquid biopsy” approach which has evolved most prominently in breast cancer will have a significant impact on early detection of cancer and treatment monitoring as well as understanding treatment failure in the near future [7]. Importantly, however, it is not only the discovery of biomarkers that counts, but also the replication and independent validation of results that allow their application in clinical practice. Last but not least, the increasing complexity of biomarker research and their potential clinical utility in the postgenomic era create a need for education of clinicians, clinical researchers, regulatory authorities, and patients alike. The amount of information requires new approaches, how biomarker use is to be understood and to be explained to those involved [8]. We believe that in this special issue we can provide fascinating reviews and original papers on the topic of biomarkers in obstetrics and gynecology and women’s cancers in the postgenomic era. It is clear that this field of research will be of increasing importance to obstetrics and gynecology and women’s cancers over the next years. We hope that this special issue with a focus on biomarker research in obstetrics and gynecology and women’s cancers will provide all participants involved in the


| Analysis                      | Purpose                                                                 |
|-------------------------------|-------------------------------------------------------------------------|
| Methylation                  | Methylation analysis can reveal disease specific patterns of gene regulation. |
| Mutation analysis            | Mutation analysis of affected tissues has been shown to be helpful in characterization of tumors and rare diseases. |
| Copy number variation        | Copy number variation has been shown to be helpful in explaining tumor subtypes and identifying fetal chromosomal anomalies. |
| Chromosomal rearrangements   | Chromosomal rearrangements are thought to explain new genomic effects seen in some tumors. |
| Genetic variation            | Many diseases have been described to be partially caused by genetic variation. For many gynecologic diseases risk loci with high and low penetrance have been identified. |
| RNA expression               | RNA expression of normal and diseased tissues has long been used to identify biomarkers for disease stage and prediction of therapies. |
| Proteomics                   | Modifications of proteins can be meaningful for their function and reveal additional functional information that supplements analysis of gene expression at the RNA level. |
| miRNA profiles               | The number of small regulatory RNA sequences is growing and miRNAs are now understood as regulators for up to several hundreds of genes at once. |

field of biomarker research with a comprehensive update on varied recent developments in this exciting field of research.

_Peter A. Fasching_
_Gottfried E. Konecny_
_Amanda B. Spurdle_

**References**

[1] P. D. Pharoah, Y. Y. Tsai, S. J. Ramus et al., “GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer,” _Nature Genetics_, vol. 45, no. 4, pp. 362–370, 2013.

[2] K. Michailidou, P. Hall, A. Gonzalez-Neira et al., “Large-scale genotyping identifies 41 new loci associated with breast cancer risk,” _Nature Genetics_, vol. 45, no. 4, pp. 353–361, 2013.

[3] Cancer Genome Atlas Research, “Integrated genomic analyses of ovarian carcinoma,” _Nature_, vol. 474, no. 7353, pp. 609–615, 2011.

[4] The Cancer Genome Atlas Network, “Comprehensive molecular portraits of human breast tumours,” _Nature_, vol. 490, no. 7418, pp. 61–70, 2012.

[5] Cancer Genome Atlas Research Network, C. Kandoth, N. Schultz et al., “Integrated genomic characterization of endometrial carcinoma,” _Nature_, vol. 497, no. 7447, pp. 67–73, 2013.

[6] K. O. Kagan, M. Hoopmann, and P. Kozlowski, “Assessment of foetal DNA in maternal blood—a useful tool in the hands of prenatal specialists,” _Geburtshilfe und Frauenheilkunde_, vol. 72, no. 11, pp. 998–1003, 2012.

[7] C. Bettegowda, M. Sausen, R. J. Leary et al., “Detection of circulating tumor DNA in early- and late-stage human malignancies,” _Science Translational Medicine_, vol. 6, no. 224, p. 224ra24, 2014.

[8] E. D. Green, M. S. Guyer, and National Human Genome Research Institute, “Charting a course for genomic medicine from base pairs to bedside,” _Nature_, vol. 470, no. 7333, pp. 204–213, 2011.
Submit your manuscripts at http://www.hindawi.com